Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DVT prophylaxis Clear all
Completed Phase 2 Interventional Results available

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725
View directory record Official record
Conditions
Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions
Odiparcil, Warfarin, Coumadin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Not applicable Interventional

High-dose Periop Statins for Prevention of DVT

NCT00259662
View directory record Official record
Conditions
Gynecologic Oncological Pelvic/Abdominal Surgery
Interventions
atorvastatin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Discharge ALERT: Quality Improvement Initiative

NCT00853463
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Prophylaxis, Venous Thromboembolism, Prevention
Interventions
Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Long Beach, California • Orange, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Dalteparin in Preventing DVT in Participants With Cancer

NCT00525057
View directory record Official record
Conditions
Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm, Pathologic Fracture, Plasma Cell Myeloma, Soft Tissue Sarcoma
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 8, 2026, 9:30 PM EDT
Completed No phase listed Observational Results available

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

NCT02596230
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
7,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Phase 4 Interventional Results available

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

NCT00966277
View directory record Official record
Conditions
Pancreatic Cancer, Venous Thromboembolism
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Wearable Technology to Reduce Risk of DVT and Increase Patient Compliance

NCT04995601
View directory record Official record
Conditions
Orthopedic Disorder
Interventions
RF Health MAC
Device
Lead sponsor
Recovery Force LLC
Industry
Eligibility
40 Years to 85 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 8, 2026, 9:30 PM EDT
Completed No phase listed Observational

Multi-Center Human Alert Trial to Prevent DVT and PE

NCT00409136
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Human Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2009 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 8, 2026, 9:30 PM EDT
Completed No phase listed Observational

3 Screen Electronic Alert

NCT00550082
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism, Cancer
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 8, 2026, 9:30 PM EDT
Recruiting Phase 2 Interventional

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

NCT06780202
View directory record Official record
Conditions
Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
Interventions
medrol dosepak, HYDROcodone Oral Tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Phase 3 Interventional

SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis

NCT00071279
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
SR34006 (idraparinux sodium) Injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
32
States / cities
Bay Pines, Florida • Brandon, Florida • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of VTE Prophylaxis

NCT03367364
View directory record Official record
Conditions
Venous Thrombosis (Disorder)
Interventions
Patient education bundle (PEB),, Nurse feedback and coaching (NFC)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Strategies for Anticoagulation During Venovenous ECMO

NCT04997265
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
Interventions
Low intensity anticoagulation, Moderate Intensity Anticoagulation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 8, 2026, 9:30 PM EDT
Recruiting Not applicable Interventional

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

NCT06451003
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Exposure to clinical decision support system and education
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

NCT00371683
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin + Placebo, Apixaban + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
3,608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Sep 8, 2026, 9:30 PM EDT
Recruiting Phase 3 Interventional

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

NCT07493304
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
REGN7508, Apixaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Hialeah, Florida • New York, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 8, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

NCT01215344
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VELCADE, Lenalidomide, Dexamethasone, DVT prophylaxis, Bisphosphonates, Liposomal doxorubicin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Memphis, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 8, 2026, 9:30 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection

NCT02123550
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Not listed
Lead sponsor
Swanson Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 8, 2026, 9:30 PM EDT
Terminated Not applicable Interventional Results available

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

NCT00521885
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily
Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 8, 2026, 9:30 PM EDT
Terminated Not applicable Interventional Results available

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

NCT03465735
View directory record Official record
Conditions
Acute DVT of Lower Extremity
Interventions
Vascular Boot, Standard of Care
Combination Product · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 8, 2026, 9:30 PM EDT